This randomised phase II trial aimed to compare efficacy of the irreversible ErbB family blocker, afatinib, with cetuximab in patients with KRAS wild–type metastatic colorectal adenocarcinoma (mCRC) with progression following oxaliplatin– and irinotecan–based regimehe efficacy of afatinib was inferior to cetuximab in patienns.

Efficacy in patients with KRAS mutations was also evaluated. Tts with KRAS wild–type mCRC. In patients with KRAS–mutated tumours, disease control was modest with afatinib. Afatinib had a manageable safety profile.

READ FULL ARTICLE Curated publisher From Mdlinx